Press Releases for ELN

Press Releases
Elan Files Declaratory Suit Against Biogen Idec; Company Has Not Breached Tysabri® Collaboration Agreement
Elan Drug Technologies announces first approval of a long acting injectable formulation using NanoCrystal® Technology
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
El Nino Ventures options Bathurst project to Votorantim Metals Canada Inc.
Elan Reports Second Quarter 2009 Financial Results
Biogen Idec Reports Second Quarter 2009 Results
Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
Elan to Showcase Its Leadership in Alzheimer’s Disease at Upcoming International Meeting
Elan Announces Webcast of Second Quarter 2009 Financial Results
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
Elan Announces Date of 2009 Annual General Meeting and Changes in Board of Directors
Elan to Present at Goldman Sachs 30th Annual Global Healthcare Conference
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFa Therapy
Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
Elan Announces Change in Board of Directors
MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
Elan Reports First Quarter 2009 Financial Results
David R. King to Receive MAC Alliance Entrepreneurial Award
MaybachFinancial.Com Posts Free Analyst Report on ELN, PKX, PH and FIS
Biogen Idec Reports First Quarter 2009 Results
Elan Announces Webcast of First Quarter 2009 Financial Results
WallStSense.Com Free Research Report for Shareholders of ELN, BXP, MAT and NWL
Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols
Elan Announces Filing of Annual Report for Year Ended December 31, 2008
Elan to Present at Cowen and Company 29th Annual Health Care Conference
El Nino Ventures identifies additional targets on the company's Kasala Project in the Democratic Republic of Congo ("DRC")
El Nino Ventures identifies additional targets on the company's Kasala Project in the Democratic Republic of Congo ("DRC")
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
El Nino Ventures joins the "AGORACOM 100" and launches online IR and marketing program - PR Newswire
El Nino Ventures joins the "AGORACOM 100" and launches online IR and marketing program - CNW
Elan Reports Fourth Quarter and Full-Year 2008 Results
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials - Jan 13 2009 8:40AM
Elan to Review Strategic Business Alternatives
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials - Jan 13 2009 1:14AM
Investment Industry Regulatory Organization of Canada - Trade Resumption - El Nino Ventures Inc. - ELN
El Nino Ventures reports high grade drill results on the Kasala Project in the Democratic Republic of Congo - PR Newswire
El Nino Ventures reports high grade drill results on the Kasala Project in the Democratic Republic of Congo - CNW
Elan Announces Webcast of Fourth Quarter and Full Year 2008 Financial Results
Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications
BridgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on WFC, ALD, ELN and C
El Nino Ventures Inc. - Corporate News
AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide
Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R)
El Nino completes acquisition in the DRC - PR Newswire
El Nino completes acquisition in the DRC - CNW
Elan to Present at the 27th Annual JP Morgan Healthcare Conference
Elan Announces Resource Realignment
Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Holzer Holzer & Fistel, LLC Announces That It Has Filed a Shareholder Class Action Against Elan Corporation, plc (NYSE: ELN)
Mary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
Carlos V. Paya, MD, PhD, to Join Elan as Company President
Scott+Scott LLP Files Class Action Lawsuit Against Elan Corporation, plc On Behalf of Investors -- ELN
El Nino Ventures Inc. - Update on exploration projects in the Democratic Republic of Congo - PR Newswire
El Nino Ventures Inc. - Update on exploration projects in the Democratic Republic of Congo - CNW
US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
Elan to Present at 2008 DB-Biotech Boston Confab
Seven Summits Research Releases Comments on PEP, ORCL, VZ, LVS, and ELN
Elan Reports Third Quarter 2008 Financial Results
Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Elan Corporation, PLC.
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Elan Corporation plc to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the December 15, 2008 Lead Plaintiff Deadline
Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Elan Corporation plc
El Nino Ventures Inc. makes significant Copper/Cobalt discovery (29 meters at 2.82% Cu and 0.34% Co) in the Democratic Republic of Congo
El Nino Ventures Inc. makes significant Copper/Cobalt discovery (29 meters at 2.82% Cu and 0.34% Co) in the Democratic Republic of Congo
Investment Industry Regulatory Organization of Canada - Trading Halt - El Nino Ventures Inc. - ELN
Elan Announces Dates for Upcoming Corporate Events
TYSABRI(R) Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
Seven Summits Research Releases Alerts on AAPL, FSLR, MET, UNH, and ELN
Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights
BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Wall Street News Alert: Breaking News Alert - VIPR! August 5, 2008
Revised Analyst Reports for CVS Caremark Corporation, The Scotts Miracle-Gro Company, McAfee Inc., And Elan Corporation Plc
Biogen Idec and Elan Will Host a Conference Call For the Investment Community
Elan and Wyeth Present Encouraging Results from Phase 2 Clinical Trial of Bapineuzumab at International Conference on Alzheimer's Disease
Elan Reports Second Quarter 2008 Financial Results
Elan and Wyeth Announce Webcast To Discuss Bapineuzumab Phase 2 Clinical Trial Results
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
El Nino Ventures Inc. makes new Acquisition in the DRC - PR Newswire
El Nino Ventures Inc. makes new Acquisition in the DRC - CNW
Seven Summits Research Releases Alerts on BAC, SLB, MOS, ELN, and NMX
Elan Announces Webcast of Second Quarter 2008 Financial Results
El Nino Ventures DRC Exploration Program Review and Update - PR Newswire
El Nino Ventures DRC Exploration Program Review and Update - CNW
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
Alzheimer's Drug Discovery Foundation Invites Scientists to Apply for Grant Award Program
Elan to Present at Goldman Sachs Global Healthcare Conference
El Nino Ventures vests with 50% interest in Bathurst claims
El Nino Ventures Inc. files amended & restated financial statements
El Nino Ventures Inc. announces release of financial results
Elan Announces Changes in Board of Directors - May 26 2008 10:31PM
Elan Reports First Quarter 2008 Financial Results
Elan to Present at the Morgan Stanley Global Healthcare Unplugged Conference and Host Company Day
Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI(R) Removal
Alzheimer's Drug Discovery Foundation and Elan Announce Winners of Third Annual Novel Discovery Award Program
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology